SCHEMBL4030407

SCHEMBL4030407

Cc1cccc(-c2nc(C)oc2-c2ccnc(Nc3ccccc3)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.42
MAPK13 O15264 2/20 0.42
MAPK12 P53778 2/20 0.42
MAPK11 Q15759 2/20 0.42
TGFBR1 P36897 7/20 0.42
KDR P35968 1/20 0.42
MAPK10 P53779 9/20 0.42
MAPK8 P45983 8/20 0.42
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
EGFR P00533 1/20 0.41
KCNH2 Q12809 1/20 0.41
MAPK9 P45984 1/20 0.37
PRKD1 Q15139 1/20 0.37
PRKD2 Q9BZL6 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.37
PIP5K1B O14986 1/20 0.37
PIP5K1C O60331 1/20 0.37
PIK3CA P42336 1/20 0.37
PIP5K1A Q99755 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030453 0.91 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL4032576 0.82 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL4034950 0.78 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL4029618 0.78 TGFBR1 (0.42) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL4031270 0.76 TGFBR1 (0.62) MAPK14TGFBR1KDRPRKD1
SCHEMBL4036011 0.76 TGFBR1 (0.63) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL6831731 0.76 MAPK10 (0.53) MAPK14MAPK13MAPK12MAPK11KDR
SCHEMBL4033475 0.76 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL4031950 0.76 MAPK14 (0.40) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL5655770 0.76 EGFR (0.44) MAPK14MAPK13MAPK12MAPK11TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542994-B1 NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR PFIZER PROD INC (US) 2009-04-29 EP claimed
EP-1542994-B1 NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR PFIZER PROD INC (US) 2009-04-29 EP disclosed
US-7273936-B2 Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors PFIZER INC. (US) 2007-09-25 US disclosed
EP-1542994-A1 NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR Pfizer Products Inc. (US) 2005-06-22 EP disclosed
US-20040110797-A1 Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors PFIZER INC 2004-06-10 US disclosed
WO-2004026863-A1 NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS PFIZER PRODUCTS INC. (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110797-A1 Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors TGFBR1, TGFBR2, SMAD3 MAPK14 319/4885MAPK13 407/4885MAPK12 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.